Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed
Magnus Nilsson,
Halla Olafsdottir,
Gabriella Alexandersson von Döbeln,
Fernanda Villegas,
Giovanna Gagliardi,
Mats Hellström,
Qiao-Li Wang,
Hemming Johansson,
Val Gebski,
Jakob Hedberg,
Fredrik Klevebro,
Sheraz Markar,
Elizabeth Smyth,
Pernilla Lagergren,
Ghazwan Al-Haidari,
Lars Cato Rekstad,
Eirik Kjus Aahlin,
Bengt Wallner,
David Edholm,
Jan Johansson,
Eva Szabo,
John V Reynolds,
CS Pramesh,
Naveen Mummudi,
Amit Joshi,
Lorenzo Ferri,
Rebecca Ks Wong,
Chris O'Callaghan,
Jelena Lukovic,
Kelvin Kw Chan,
Trevor Leong,
Andrew Barbour,
Mark Smithers,
Yin Li,
Xiaozheng Kang,
Feng-Ming Kong,
Yin-Kai Chao,
Tom Crosby,
Christiane Bruns,
Hanneke van Laarhoven,
Mark van Berge Henegouwen,
Richard van Hillegersberg,
Riccardo Rosati,
Guillaume Piessen,
Giovanni de Manzoni,
Florian Lordick
Jul 27, 2022
BACKGROUND: The globally dominant treatment with curative intent for locally advanced esophageal squamous cell carcinoma (ESCC) is neoadjuvant chemoradiotherapy (nCRT) with subsequent esophagectomy. This multimodal treatment...